HopeStage
Back to all studies
CompletedNCT00320671

Aripiprazole or risperidone for first-episode psychosis

About this titleRead the official source — NCT00320671
Medication studyAges 15–40United StatesSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 15 years to 40 years.

Listed locations
Glen OaksSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateDecember 2005
Recruitment status
Completed
Enrollment listed in the registry
198
Sponsor
Northwell Health
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 15 Years to 40 Years
Official registry ID
NCT00320671
Official title
Show the full official title

Preventing Morbidity in First Episode Schizophrenia, Part II

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Glen Oaks

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Northwell Health.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole and Risperidone.

Who was this study for?

Listed age limits: 15 years to 40 years.

Want to explore more studies?

Explore studies